K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · VRTX
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | TARPLIN, DOWNS & YOUNG, LLC | $80K | Federal budget issues Alternatives to PAIN Act, IRA, innovation, health disparities, orphan drugs, drug pricing in federal programs, opioid alternative medicines, awareness of rare kidney disorders Medicare & Medicaid payment and coverage issues |
| 2026-04-20 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | CGCN GROUP, LLC | $80K | Access to innovative non-opioid medicines. Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475. |
| 2026-04-20 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | AVENUE SOLUTIONS | $60K | Monitor issues related to 340b; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders and expiring Advanced Premium Tax Credits (APTC) H.R. 1227/S. 475, Alternatives to PAIN Act and issues related to payment policies for non-opioid pain medication; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process |
| 2026-04-20 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | STANTON PARK GROUP | $50K | Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; HR 1227 and S. 375 |
| 2026-04-20 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | CROSSROADS STRATEGIES, LLC | $30K | General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about precision medicine. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about non-opioid pain therapies.H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about the importance of access to non-opioid pain therapies for Medicare beneficiaries. H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act. |
| 2026-04-20 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | ALSTON & BIRD LLP | $20K | FY2027 Appropriations bills. FY2027 Appropriations bills. |
| 2026-04-20 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | MCLARTY INBOUND LLC | $0 | |
| 2026-04-19 | VRTX | TIBER CREEK GROUP (ON BEHALF OF VERTEX PHARMACEUTICALS) | TIBER CREEK HEALTH STRATEGIES, INC. | $60K | |
| 2026-04-19 | VRTX | VERTEX PHARMACEUTICALS | TIBER CREEK GROUP | $60K | Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act; Issues related to H.R. 1518 - New Era of Preventing End-Stage Kidney Disease Act. Issues related to coverage of opioid alternatives. |
| 2026-04-18 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | EMPIRE CONSULTING GROUP | $50K | HR 1227, Alternatives to PAIN Act. |
| 2026-04-17 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | VERTEX PHARMACEUTICALS INCORPORATED | $1.1M | Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments. Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals. Corporate tax reform; H.R. 1414 - Cameron's Law, Preservation of Orphan Drug Tax Credit. Education about non-opioid pain therapies and patient access to non- |
| 2026-04-17 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | MARSHALL & POPP, LLC | $60K | Issues related to pain management, including S.475/H.R. 1227 - Alternatives to PAIN Act. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. |
| 2026-04-17 | VRTX | VERTEX PHARMACEUTICALS | SALT POINT STRATEGIES | $10K | Non-opioid pain relief and drug pipeline issues. |
| 2026-04-15 | VRTX | VERTEX PHARMACEUTICALS | ALB SOLUTIONS | $50K | Non-opioid pain relief and drug pipeline issues. |
| 2026-04-10 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | HOLLAND & KNIGHT LLP | $20K | Tax Reform - Restoring the Orphan Drug Tax Credit. |
| 2026-03-20 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | ALSTON & BIRD LLP | $0 | FY2027 Appropriations bills. FY2027 Appropriations bills. |
| 2026-03-10 | VRTX | VERTEX PHARMACEUTICALS | ALB SOLUTIONS | $0 | Non-opioid pain relief and drug pipeline issues. |
| 2026-01-20 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | TARPLIN, DOWNS & YOUNG, LLC | $80K | Federal budget issues Alternatives to PAIN Act, IRA, innovation, health disparities, orphan drugs, drug pricing in federal programs, opioid alternative medicines, SUPPORT Act reauthorization, awareness of rare kidney disorders Medicare & Medicaid payment and coverage issues |
| 2026-01-20 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | CGCN GROUP, LLC | $80K | Access to innovative non-opioid medicines. Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475. |
| 2026-01-20 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | AVENUE SOLUTIONS | $60K | Monitor issues related to 340b; Expiring healthcare extenders H.R. 1227/S. 475, Alternatives to PAIN Act and issues related to payment policies for non-opioid pain medication; Issues related to Most Favored Nation (MFN) drug pricing proposal |
| 2026-01-20 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | STANTON PARK GROUP | $50K | Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; HR 7142 and S. 3832 |
| 2026-01-20 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | MCLARTY INBOUND LLC | $0 | |
| 2026-01-19 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | EMPIRE CONSULTING GROUP | $30K | HR 1227, Alternatives to PAIN Act. |
| 2026-01-19 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | CROSSROADS STRATEGIES, LLC | $30K | General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about non-opioid pain therapies.H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about precision medicine. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about the importance of access to non-opioid pain therapies for Medicare beneficiaries. H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act. |
| 2026-01-18 | VRTX | VERTEX PHARMACEUTICALS | SALT POINT STRATEGIES | $40K | Non-opioid pain relief and drug pipeline issues. |
| 2026-01-17 | VRTX | VERTEX PHARMACEUTICALS | TIBER CREEK GROUP | $60K | Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act. Issues related to opioid alternatives; Issues related to the National Defense Authorization Act for Fiscal Year 2026 (PL 119-60). |
| 2026-01-17 | VRTX | TIBER CREEK GROUP (ON BEHALF OF VERTEX PHARMACEUTICALS) | TIBER CREEK HEALTH STRATEGIES, INC. | $60K | |
| 2026-01-16 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | MARSHALL & POPP, LLC | $60K | Issues related to pain management, including S.475/H.R. 1227 - Alternatives to PAIN Act. |
| 2026-01-13 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | VERTEX PHARMACEUTICALS INCORPORATED | $1.1M | Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments. Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals. Corporate tax reform; H.R. 1414 - Cameron's Law, Preservation of Orphan Drug Tax Credit; Restoration of Sec 174 R&D Expense Deductibility. Education about non-opioid pain therapies and patient access to non-opioid medici |
| 2026-01-13 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | HOLLAND & KNIGHT LLP | $20K | Tax Reform - Restoring the Orphan Drug Tax Credit. |
| 2025-10-20 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | MCLARTY INBOUND LLC | $90K | Supporting Vertex on trade-related issues. |
| 2025-10-20 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | TARPLIN, DOWNS & YOUNG, LLC | $80K | Federal budget issues Alternatives to PAIN Act, IRA, innovation, health disparities, orphan drugs, 340B, opioid alternative medicines, SUPPORT Act reauthorization, awareness of rare kidney disorders Medicare & Medicaid payment and coverage issues |
| 2025-10-20 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | CGCN GROUP, LLC | $80K | Access to innovative non-opioid medicines. Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475. |
| 2025-10-20 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | MARSHALL & POPP, LLC | $60K | Issues related to pain management, including S.475/H.R. 1227 - Alternatives to PAIN Act. |
| 2025-10-20 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | AVENUE SOLUTIONS | $60K | H.R. 1227/S. 475, Alternatives to PAIN Act and issues related to payment policies for non-opioid pain medication; Issues related to Most Favored Nation (MFN) drug pricing proposal Monitor issues related to 340b; Expiring healthcare extenders |
| 2025-10-20 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | STANTON PARK GROUP | $50K | Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; HR 7142 and S. 3832 |
| 2025-10-20 | VRTX | VERTEX PHARMACEUTICALS | SALT POINT STRATEGIES | $30K | Non-opioid pain relief and drug pipeline issues. |
| 2025-10-19 | VRTX | TIBER CREEK GROUP (ON BEHALF OF VERTEX PHARMACEUTICALS) | TIBER CREEK HEALTH STRATEGIES, INC. | $60K | |
| 2025-10-19 | VRTX | VERTEX PHARMACEUTICALS | TIBER CREEK GROUP | $60K | Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act. Issues related to opioid alternatives; Issues related to H.R. 3838 - Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026; Issues related to S. 2296 - National Defense Authorization Act for Fiscal Year 2026. |
| 2025-10-19 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | EMPIRE CONSULTING GROUP | $30K | HR 1227, Alternatives to PAIN Act. |
| 2025-10-19 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | CROSSROADS STRATEGIES, LLC | $30K | General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about non-opioid pain therapies.H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about precision medicine. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about the importance of access to non-opioid pain therapies for Medicare beneficiaries. H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act. |
| 2025-10-15 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | HOLLAND & KNIGHT LLP | $20K | Tax Reform - Restoring the Orphan Drug Tax Credit. |
| 2025-10-14 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | VERTEX PHARMACEUTICALS INCORPORATED | $1.1M | Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, S.864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments. Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals. Corporate tax reform; H.R. 1414 - Cameron's Law, Preservation of Orphan Drug Tax Credit; Restoration of Sec 174 R&D Expense Deductibility. Education about non-opioid pain therapies and patient access to non-opioid medicines; Educat |
| 2025-10-09 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | VERTEX PHARMACEUTICALS INCORPORATED | $1.1M | Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, S.864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments. Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals; Issues regarding the One Big Beautiful Bill Act (PL 119-21). Corporate tax reform; H.R. 1414 - Cameron's Law, Preservation of Orphan Drug Tax Credit; Restoration of Sec 174 R&D Expense Deductibility; Issues related to the One Big Bea |
| 2025-07-21 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | MCLARTY INBOUND LLC | $90K | Supporting Vertex on trade-related issues. |
| 2025-07-21 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | TARPLIN, DOWNS & YOUNG, LLC | $80K | Federal budget issues Alternatives to PAIN Act, IRA, innovation, health disparities, orphan drugs, 340B, opioid alternative medicines, SUPPORT Act reauthorization, awareness of rare kidney disorders Medicare & Medicaid payment and coverage issues |
| 2025-07-21 | VRTX | VERTEX PHARMACEUTICALS | TIBER CREEK GROUP | $80K | Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act. Issues related to opioid alternatives; Issues related to H.R. 3838 - SPEED Act; Issues related to S. 2296 - National Defense Authorization Act for Fiscal Year 2026. |
| 2025-07-21 | VRTX | TIBER CREEK GROUP (ON BEHALF OF VERTEX PHARMACEUTICALS) | TIBER CREEK HEALTH STRATEGIES, INC. | $80K | |
| 2025-07-21 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | MARSHALL & POPP, LLC | $60K | Issues related to pain management, including S.475/H.R. 1227 - Alternatives to PAIN Act. H.R. 1, FY25 budget reconciliation. |
| 2025-07-21 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | AVENUE SOLUTIONS | $60K | H.R. 1227/S. 475, Alternatives to PAIN Act and issues related to payment policies for non-opioid pain medication; H.R. 1672, Maintaining Investments in New Innovation Act; Biosimilars Access and Affordability Act; H.R. 2484, Seniors Access to Critical Medications Act; H.R. 946/S. 1862, ORPHAN Cures Act; Issues related to PBM reform; Issues related to Most Favored Nation (MFN) drug pricing proposal Monitor issues related to 340b; Health care issues in H.R. 1, To provide for reconciliation pursuant to title II of H. Con. Res. 14 (Public Law No: 119-21) |
| 2025-07-21 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | STANTON PARK GROUP | $50K | Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; HR 7142 and S. 3832 |
| 2025-07-19 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | CGCN GROUP, LLC | $75K | Access to innovative non-opioid medicines. Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475. |
| 2025-07-19 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | CROSSROADS STRATEGIES, LLC | $30K | General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about non-opioid pain therapies.H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about precision medicine. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about the importance of access to non-opioid pain therapies for Medicare beneficiaries. H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act. |
| 2025-07-18 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | EMPIRE CONSULTING GROUP | $40K | HR 1227, Alternatives to PAIN Act. |
| 2025-07-16 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | VERTEX PHARMACEUTICALS INCORPORATED | $1.1M | Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, S.864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments. Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals; Issues regarding the One Big Beautiful Bill Act (PL 119-21). Corporate tax reform; H.R. 1414 - Cameron's Law, Preservation of Orphan Drug Tax Credit; Restoration of Sec 174 R&D Expense Deductibility; Issues related to the One Big Bea |
| 2025-07-16 | VRTX | VERTEX PHARMACEUTICALS | SALT POINT STRATEGIES | $30K | Non-opioid pain relief and drug pipeline issues. |
| 2025-07-13 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | HOLLAND & KNIGHT LLP | $20K | Tax Reform - Restoring the Orphan Drug Tax Credit. |
| 2025-04-21 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | AVENUE SOLUTIONS | $60K | H.R. 1227/S. 475, Alternatives to PAIN Act and issues related to payment policies for non-opioid pain medication; H.R. 1672, Maintaining Investments in New Innovation Act; Biosimilars Access and Affordability Act; H.R. 2484, Seniors Access to Critical Medications Act; H.R. 946, ORPHAN Cures Act; Issues related to PBM reform Monitor issues related to 340b; S. 891, Bipartisan Health Care Act; H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (PL 119-4) |
| 2025-04-21 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | STANTON PARK GROUP | $50K | Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; HR 7142 and S. 3832 |
| 2025-04-21 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | MARSHALL & POPP, LLC | $40K | Issues related to pain management, including S.475/H.R. 1227 - Alternatives to PAIN Act. |
| 2025-04-21 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | CROSSROADS STRATEGIES, LLC | $30K | General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about non-opioid pain therapies.H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about non-opioid pain therapies.H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about non-opioid pain therapies.H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act. |
| 2025-04-20 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | TARPLIN, DOWNS & YOUNG, LLC | $80K | Federal budget issues Alternatives to PAIN Act, IRA, innovation, health disparities, orphan drugs, 340B, opioid alternative medicines, SUPPORT Act reauthorization, awareness of rare kidney disorders Medicare & Medicaid payment and coverage issues |
| 2025-04-19 | VRTX | VERTEX PHARMACEUTICALS | TIBER CREEK GROUP | $80K | Issues related to drug pricing; Issues related to H.R. 7142/S. 3832 - Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act. Issues related to opioid alternatives. |
| 2025-04-19 | VRTX | VERTEX PHARMACEUTICALS | SALT POINT STRATEGIES | $30K | Non-opioid pain relief and drug pipeline issues. |
| 2025-04-19 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | CGCN GROUP, LLC | $30K | Access to innovative non-opioid medicines. Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475. |
| 2025-04-18 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | VERTEX PHARMACEUTICALS INCORPORATED | $1.6M | Unmet medical need in acute pain; H.R.1227/S.475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease. Issues related to corporate tax reform. Education about non-opioid pain therapies and patient access to non-opioid medicines, education on alternative funding programs, education on the Million Veteran Program at the VA. Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (S.864); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments. |
| 2025-04-18 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | EMPIRE CONSULTING GROUP | $50K | HR 1227, Alternatives to PAIN Act; issues related to CMMIs Cell and Gene Therapy Access model for Sickle Cell Disease. |
| 2025-04-18 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | MCLARTY INBOUND LLC | $20K | Supporting Vertex on trade-related issues. |
| 2025-04-17 | VRTX | TIBER CREEK GROUP (ON BEHALF OF VERTEX PHARMACEUTICALS) | TIBER CREEK HEALTH STRATEGIES, INC. | $80K | Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169). |
| 2025-04-12 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | HOLLAND & KNIGHT LLP | $20K | Tax Reform - Restoring the Orphan Drug Tax Credit. |
| 2025-04-03 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | MCLARTY INBOUND LLC | $0 | Supporting Vertex on trade-related issues. |
| 2025-03-24 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | MARSHALL & POPP, LLC | $0 | Issues related to pain management. Issues related to pain management. Issues related to pain management. Issues related to pain management. |
| 2025-02-24 | VRTX | VERTEX PHARMACEUTICALS | SALT POINT STRATEGIES | $0 | Non-opioid pain relief and drug pipeline issues. |
| 2025-01-21 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | AVENUE SOLUTIONS | $60K | H.R. 7142/S. 3832, Alternatives to PAIN Act and issues related to payment policies for non-opioid pain medication; S. 2973, The Modernizing and Ensuring PBM Accountability (MEPA) Act; H.R. 5378, The Lower Costs, More Transparency Act Monitor S. 1339, Pharmacy Benefit Manager Reform Act; Monitor issues related to 340b; Expiring healthcare extenders; H.R. 10545, American Relief Act, 2025 |
| 2025-01-21 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | STANTON PARK GROUP | $50K | Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; HR 7142 and S. 3832 |
| 2025-01-20 | VRTX | TIBER CREEK GROUP (ON BEHALF OF VERTEX PHARMACEUTICALS) | TIBER CREEK HEALTH STRATEGIES, INC. | $80K | Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169). |
| 2025-01-20 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | CGCN GROUP, LLC | $25K | Access to innovative non-opioid medicines. Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 714; Alternatives to PAIN, S. 3832 |
| 2025-01-19 | VRTX | VERTEX PHARMACEUTICALS | TIBER CREEK GROUP | $80K | Issues related to drug pricing; Issues related to H.R.7142/S.3832 - Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act. |
| 2025-01-19 | VRTX | VERTEX PHARMACEUTICALS INCORPORATED | HOLLAND & KNIGHT LLP | $10K | Tax Reform - Restoring the Orphan Drug Tax Credit. |